Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 6/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 5/20 | 0.47 |
| ▸ | CA2 | P00918 | 5/20 | 0.47 |
| ▸ | CA9 | Q16790 | 5/20 | 0.47 |
| ▸ | CA12 | O43570 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16367327 | 0.90 | CHRM1 (0.59) | MAPK1ATMEGFRERBB2CHRM1 | |
| SCHEMBL16367326 | 0.85 | MAPK1 (0.61) | MAPK1ATMEGFRERBB2CHRM1 | |
| SCHEMBL16367353 | 0.84 | EGFR (0.52) | MAPK1ATMEGFRERBB2CHRM1 | |
| SCHEMBL15607811 | 0.81 | EGFR (0.36) | MAPK1ATMEGFRERBB2CHRM1 | |
| SCHEMBL9232636 | 0.80 | CA1 (0.70) | MAPK1EGFRERBB2ALDH1A1LMNA | |
| SCHEMBL16367378 | 0.78 | MMP2 (0.36) | EGFRERBB2ALDH1A1CA1CA2 | |
| SCHEMBL16367390 | 0.77 | L3MBTL1 (0.38) | EGFRERBB2ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL16367296 | 0.77 | KMT2A (0.47) | ALDH1A1LMNATHRBCA1CA2 | |
| SCHEMBL16367344 | 0.76 | MAPK1 (0.72) | MAPK1ATMEGFRERBB2CHRM1 | |
| SCHEMBL16367328 | 0.76 | MAPK1 (0.72) | MAPK1ATMCHRM1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | CBR1, CBR3, BLVRB | MAPK1 3155/4885ATM 4802/4885EGFR 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.